论文部分内容阅读
目的:观察吉非替尼(Iressa)单药治疗非小细胞肺癌(NSCLC)患者的近远期疗效及毒副反应。方法:48例均经病理组织学确诊的NSCLC患者,口服吉非替尼单药250mg,1次/d,2个月后评价疗效及评价后4周疗效确认,停用吉非替尼的标准为疾病进展或不良反应不能耐受。结果:48例患者均可评价疗效,CR4例,PR16例,总有效率(RR)为41.6%,SD16例,疾病控制率(DCR)为75.0%,PD12例,性别、病理类型、吸烟史和年龄等因素都与近期有效率(RR)相关。有效患者的中位缓解时间为12个月(95%CI为5.6～16.6个月),中位生存期为12.5个月(95%CI为8.6～14.2个月),中位肿瘤进展时间为8.4个月(95%CI为4.1～10.2个月),1年生存率为42.6%。生活质量明显改善。与药物相关的不良反应依次为皮疹、腹泻、恶心、关节痛和肝功能异常。结论:吉非替尼治疗疗效明确。毒副反应较轻,耐受性较好,可以明显改善患者生存质量,作为NSCLC的治疗药物值得推广。
Objective: To observe the short-term and long-term effects and adverse reactions of Iressa monotherapy in patients with non-small cell lung cancer (NSCLC). Methods: Forty-eight NSCLC patients were diagnosed by histopathology. Gefitinib monotherapy was given 250 mg once daily for 2 months. The curative effect was evaluated after 2 months and the curative effect was confirmed 4 weeks after the evaluation. Gefitinib was discontinued Not tolerate disease progression or adverse reactions. Results: The curative effect was evaluated in 48 patients. The CR4 and PR16 cases had a total effective rate (RR) of 41.6%, SD16 cases and disease control rate (DCR) of 75.0%. There were 12 cases of PD, sex, pathological type, Age and other factors are related to recent efficiency (RR). The median effective response time for patients was 12 months (95% CI 5.6 to 16.6 months), median survival 12.5 months (95% CI 8.6-14.2 months), and the median time to tumor progression was 8.4 Month (95% CI: 4.1-10.2 months), and the one-year survival rate was 42.6%. Quality of life improved significantly. Drug-related adverse reactions followed by rash, diarrhea, nausea, joint pain and liver dysfunction. Conclusion: Gefitinib treatment has clear effect. Toxicity and mild side effects, better tolerated, can significantly improve the quality of life of patients, as the treatment of NSCLC worth promoting.